Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from...

Read More